Prodigiosin release from an implantable biomedical device: kinetics of localized cancer drug release

Danyuo, Y.; Obayemi, John D.; Dozie-Nwachukwu, S.; Ani, C.J.; Odusanya, Olushola S.; Oni, Y.; Anuku, N.; Malatesta, Karen; Soboyejo, W. O.

doi:10.1016/j.msec.2014.06.008

Cited by 26 publications

(31 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prodigiosin (PGS) which is also known as 4-methoxy-5-[(Z)-(5-methyl-4-pentyl-2H-pyrrol-2-ylidene)methyl]-1H,1′H-2,2′-bipyrrole contains a C-6 methoxy substituent in the 4-methoxy-2,20-bipyrrolyl ring. The purity of the prodigiosin that was synthesized for conjugation to LHRH was characterized to be 92.5% 35,36 . The presence of the hydrophilic linker (NHS) creates sites for reactions with the methoxy group that is present in the prodigiosin molecule 37 .…”

Section: Resultsmentioning

confidence: 99%

“…Materials. Prodigiosin was biosynthesized from Serratia marcescens 35,36 , while paclitaxel, Experimental procedure. Prodigiosin synthesis and conjugation.…”

Section: Methodsmentioning

confidence: 99%

“…Prodigiosin synthesis and conjugation. Prodigiosin (PGS) was synthesized in the Soboyejo Research Group at WPI, as reported in our previous work 35,36 . A PGS concentration of 31.15 mg/ml was prepared with DMSO.…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

LHRH-Conjugated Drugs as Targeted Therapeutic Agents for the Specific Targeting and Localized Treatment of Triple Negative Breast Cancer

Obayemi

Salifu

Eluu

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Bulk chemotherapy and drug release strategies for cancer treatment have been associated with lack of specificity and high drug concentrations that often result in toxic side effects. This work presents the results of an experimental study of cancer drugs (prodigiosin or paclitaxel) conjugated to Luteinizing Hormone-Releasing Hormone (LHRH) for the specific targeting and treatment of triple negative breast cancer (TNBC). Injections of LHRH-conjugated drugs (LHRH-prodigiosin or LHRH-paclitaxel) into groups of 4-week-old athymic female nude mice (induced with subcutaneous triple negative xenograft breast tumors) were found to specifically target, eliminate or shrink tumors at early, mid and late stages without any apparent cytotoxicity, as revealed by in vivo toxicity and ex vivo histopathological tests. Our results show that overexpressed LHRH receptors serve as binding sites on the breast cancer cells/ tumor and the LHRH-conjugated drugs inhibited the growth of breast cells/tumor in in vitro and in vivo experiments. The inhibitions are attributed to the respective adhesive interactions between LHRH molecular recognition units on the prodigiosin (PGS) and paclitaxel (PTX) drugs and overexpressed LHRH receptors on the breast cancer cells and tumors. The implications of the results are discussed for the development of ligand-conjugated drugs for the specific targeting and treatment of TNBC. Breast cancer is the most commonly diagnosed cancer and the second most frequent cause of death in women 1. In general, breast tumors are intrinsically heterogeneous in nature, making them difficult to detect and treat 2. Approximately, 75-80% of breast cancers are hormone receptor-positive 2,3. Also, these overexpressed receptors are usually estrogen and/or progesterone receptors 2,3. However, Triple Negative Breast Cancer (TNBC) (which represents approximately 10-17% of all breast cancers) does not express estrogen receptors (ER), or progesterone receptors (PR), or the human epidermal growth factor receptor 2 gene (HER2) 4-8. In addition, TNBCs also exhibit distinctive clinical features 7,8 and are more common in younger patients 6 and African American/African women 9. TNBC is an aggressive and immunopathology subtype of breast cancer that usually does not respond to drugs that target ER, PR and HER2 6. Furthermore, since the most common and conventional breast cancer diagnosis and treatment techniques tend to focus and target ER, PR and HER2, it is often difficult to detect 10 and treat 11 TNBCs with conventional targeted hormonal therapy and chemotherapy. The challenges associated with TNBCs

show abstract

Section: Resultsmentioning

confidence: 99%

“…Materials. Prodigiosin was biosynthesized from Serratia marcescens 35,36 , while paclitaxel, Experimental procedure. Prodigiosin synthesis and conjugation.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

LHRH-Conjugated Drugs as Targeted Therapeutic Agents for the Specific Targeting and Localized Treatment of Triple Negative Breast Cancer

Obayemi

Salifu

Eluu

et al. 2020

Sci Rep

View full text Add to dashboard Cite

show abstract

“…We have reported different in-vitro simultaneous hyperthermia and drug release studies. [ 13 , 15 ] As with the previous device, the conditions of hyperthermia were achieved based on Joule heating. In a proof of concept experiment, the pulsatile release of rhodamine dye from the device was compared to an unencapsulated PNIPA gel.…”

Section: Polymer-metal Compositesmentioning

confidence: 99%

“…Furthermore, the duration of drug release can be controlled by varying the length and shape of the channels in the PDMS shell as shown by our experiments. [ 13 , 15 ] The current device under discussion is designed such that there will be no need for its removal after all the drugs have been released. The intention is to reuse the device in the event that the cancer cells reoccur.…”

Section: Polymer-metal Compositesmentioning

confidence: 99%

Polymeric composite devices for localized treatment of early-stage breast cancer

2017

View full text Add to dashboard Cite

For early-stage breast cancers mastectomy is an aggressive form of treatment. Therefore, there is a need for new treatment strategies that can enhance the use of lumpectomy by eliminating residual cancer cells with limited side effects to reduce local recurrence. Although, various radiotherapy-based methods have been developed, residual cells are found in 20–55% of the time at the first operation. Furthermore, some current treatment methods result in poor cosmesis. For the last decade, the authors have been exploring the use of polymeric composite materials in single and multi-modal implantable biomedical devices for post-operative treatment of breast cancer. In this paper, the concept and working principles of the devices, as well as selected results from experimental and numerical investigations, are presented. The results show the potential of the biomedical implants for cancer treatment.

show abstract

The Impact of Implantable Sensors in Biomedical Technology on the Future of Healthcare Systems

Darwish

Sayed

Hassanien

2019

Intelligent Pervasive Computing Systems for Smarter Healthcare

View full text Add to dashboard Cite

Prodigiosin release from an implantable biomedical device: kinetics of localized cancer drug release

Cited by 26 publications

References 22 publications

LHRH-Conjugated Drugs as Targeted Therapeutic Agents for the Specific Targeting and Localized Treatment of Triple Negative Breast Cancer

LHRH-Conjugated Drugs as Targeted Therapeutic Agents for the Specific Targeting and Localized Treatment of Triple Negative Breast Cancer

Polymeric composite devices for localized treatment of early-stage breast cancer

The Impact of Implantable Sensors in Biomedical Technology on the Future of Healthcare Systems

Contact Info

Product

Resources

About